Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including…

Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.

Children with a rare, devastating brain disease may soon have their first treatment option in BioMarin’s Brineura.

Valeant unveiled the sticker on its new psoriasis drug Siliq—and at $3,500 per month it’s the lowest for next-gen meds.

UniQure's trailblazing gene therapy has met its end. After struggling for years with the ultraexpensive Glybera, the company is calling it quits on the…

It was destined to happen: Amgen has sued Sanofi and Regeneron, claiming their newly approved Dupixent infringes one of its antibody patents.

Pharma largely continued its price-hiking ways in 2016, and no wonder: The corresponding sales windfall equated to 100% of the industry’s overall earnings-per-…

Biogen's Spinraza raised eyebrows for a $750,000 first-year price, but rare disease medications are expensive, period. Check out this list.

Launches